Genoscience Pharma

Executive Summary

Genoscience Pharma is a French clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target lysosomal functions to disrupt nutrient supply to cancer and fibrotic cells. Founded in 2008 and headquartered in Marseille, the company's lead program is in Phase 1 for oncology, with additional preclinical programs in fibrosis. Its innovative mechanism addresses high unmet needs by depriving diseased cells of essential nutrients, potentially offering a differentiated approach. Early clinical data are awaited to validate the platform's safety and efficacy. With a strong focus on precision medicine and a robust intellectual property portfolio, Genoscience is positioned to advance its pipeline through clinical development, though the early-stage nature implies significant risk. The company seeks partnerships or funding to support its ongoing and planned trials, notably in cholangiocarcinoma and other hard-to-treat cancers.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 data readout for lead candidate in solid tumors60% success
• Q3 2026IND approval for a new fibrosis indication50% success
• Q4 2026Strategic partnership or licensing deal for Asian markets40% success